Skip to main content
SpringerLink
Log in

Prostate Cancer and Combined Androgen Blockade at All Stages of Disease

  • Chapter
Progress in Anti-Cancer Chemotherapy

Part of the book series: Progress in Anti-Cancer Chemotherapy ((ANTI-CANCER,volume 4))

Abstract

The first observation of the role of male hormones in prostate cancer was made by Huggins and his colleagues in 1941 (Huggins and Hodges, 1941; Huggins et al, 1941). They then observed some dramatic responses in metastatic prostate cancer patients treated by castration or estrogens. During the 50 years that followed the introduction of the concept of androgen dependency of prostate cancer by Huggins, orchiectomy (surgical castration) and high doses of estrogens have remained the gold standard for the treatment of advanced prostate cancer (Fig. 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bélanger A, Brochu M, Cliche J (1986) Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. J Clin Endocrinol Metab 62:812–815

    Article  PubMed  Google Scholar 

  • Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD (1999) Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer and Prostatic Diseases 2:4–8

    Article  PubMed  Google Scholar 

  • Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl J Med 337:295–300

    Article  PubMed  CAS  Google Scholar 

  • Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD (1997) Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49:71–78

    Article  PubMed  CAS  Google Scholar 

  • Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein DA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424

    Article  PubMed  CAS  Google Scholar 

  • Denis L, Carnelro de Moura JL, Bono A, Sylvester R, Whelan R, Newling D, De Pauw M (1993) Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 42:119–129

    CAS  Google Scholar 

  • Denis LJ, Keuppens F, Smith PH, Whelan P, Carneiro de Moura JL, Newling D, Bono A, Sylvester R (1998) Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. Eur Urol 33:144–151

    Article  PubMed  CAS  Google Scholar 

  • Dijkman GA, Janknegt RA, Dereijke TM, Debruyne FMJ (1997) Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization. J Urol 158:160–163

    Article  PubMed  CAS  Google Scholar 

  • Dupont A, Cusan L, Gomez JL, Koutsilieris M, Suburu R, Emond J, Labrie F (1993) Combination therapy with Flutamide and the LHRH agonist [D-Trp6-des-Gly-NH2]LHRH ethylamide in stage C prostatic carcinoma. Brit J Urol 72:629–634

    Article  PubMed  CAS  Google Scholar 

  • Faure N, Labrie F, Lemay A, Bélanger A, Gourdeau Y, Laroche B, Robert G (1982) Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (GNRH) agonist in adult men. Fertil Steril 37:416–424, 1982

    PubMed  CAS  Google Scholar 

  • Goad JR, Chang SJ, Ohori M, Scardino PT (1993) PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am 20:727–736

    PubMed  CAS  Google Scholar 

  • Huggins C, Hodges CV (1941) Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–307

    CAS  Google Scholar 

  • Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209–223

    CAS  Google Scholar 

  • Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM et al. (1993) Orchiectomy and Nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 149:77–83

    PubMed  CAS  Google Scholar 

  • Kaplan ID, Cox RS, Bagshaw MA (1993) Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. J Urol 149:519–522

    PubMed  CAS  Google Scholar 

  • Kupelian P, Katcher J, Levin H, Zippe C, Klein E (1996) Correlation of clinical and pathological factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48:249–260

    Article  PubMed  CAS  Google Scholar 

  • Labrie F, Bélanger A, Cusan L, Séguin C, Pelletier G, Kelly PA, Reeves JJ, Lefebvre FA, Lemay, A, Ranaud JP (1980) Antifertility effects of LHRH agonists in the male. J Androl 1:209–228

    CAS  Google Scholar 

  • Labrie F, Bélanger A, Cusan L, Simard J, Luu-The V, Labrie C, Gomez JL, Diamond P, Candas B (1996a) History of LHRH agonist and combination therapy in prostate cancer. Endocrine-Related Cancer 3:243–278

    Article  CAS  Google Scholar 

  • Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M (1996b) Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 47 212–217

    Article  PubMed  CAS  Google Scholar 

  • Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Lévesque J, Diamond P, Bélanger A (1999) Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. The Prostate 38:83–91

    Article  PubMed  CAS  Google Scholar 

  • Labrie F, Crawford D (1995) Anti-androgens in treatment of prostate cancer. Lancet 346:1030–1031

    Article  PubMed  CAS  Google Scholar 

  • Labrie F, Cusan L, Gomez JL, Diamond P, Bélanger A (1997) Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol Urol 1:253–261

    CAS  Google Scholar 

  • Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Candas B (1994) Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44:29–37

    Article  Google Scholar 

  • Labrie F, Dupont A, Bélanger A (1985) Complete androgen blockade for the treatment of prostate cancer, in de Vita VT, Hellman S and Rosenberg SA, eds: Important Advances in Oncology, Philadelphia, J.B. Lippincott, pp 193–217

    Google Scholar 

  • Labrie F, Dupont A, Bélanger A, Cusan L, Lacourciére Y, Monfette G, Laberge JG, Emond J, Fazekas AT, Raynaud JP, Husson JM (1982) New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5:267–275

    PubMed  CAS  Google Scholar 

  • Labrie F, Dupont A, Bélanger A, Emond J, Monfette G, Luthy I, Simard J, Lachance R (1987) Flutamide in combination with castration (surgical or medical) is the standard treatment in advanced prostate cancer. J Drug Develop 1:34–51

    Google Scholar 

  • Labrie F, Dupont A, Bélanger A, Lacourcière Y, Raynaud JP, Husson JM, Gareau J, Fazekas AT, Sandow J, Monfette G, Girard JG, Emond J, Houle JG (1983) New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. Prostate 4:579–594

    Article  PubMed  CAS  Google Scholar 

  • Laverdiere J, Gomez JL, Cusan L, Suburu R, Diamond P, Lemay M, Candas B, Fortin A, Labrie F (1997) Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37:247–252

    Article  PubMed  CAS  Google Scholar 

  • Lee F, Torp-Pedersen ST, Siders DB, Littrup PJ, McLeary RD (1989) Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology 170:609–615

    PubMed  CAS  Google Scholar 

  • Morton RA, Steiner MS, Walsh PC (1991) Cancer control following anatomical radical prostatectomy: an interim report. J Urol 145:1197–1200

    PubMed  CAS  Google Scholar 

  • Peeling WB (1989) Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 33:45–52

    Article  PubMed  CAS  Google Scholar 

  • Prostate Cancer Triallists’ Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 346:265–269

    Google Scholar 

  • Prostate Cancer Triallists’ Collaborative Group: Update of data. Unpublished, 1997

    Google Scholar 

  • Robinson MR, Thomas BS (1971) Effect of hormone therapy on plasma testosterone levels in prostatic cancer. Br Med J 4:391–394

    Article  PubMed  CAS  Google Scholar 

  • Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas ATA, Comaru-Schally AM, Schally AV (1982) Tumor growth inhibition in patients with prostatic carcinoma treated with LHRH agonists. Proc Natl Acad Sci 79:1658–1662

    Article  PubMed  CAS  Google Scholar 

  • Trapasso JG, deKernion JB, Smith RB, Dorey F (1994) The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821–1825

    PubMed  CAS  Google Scholar 

  • VACURG (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011–1017

    Google Scholar 

  • Waxman JH, Wass JA, Hendry WF, Whitfield HN, Besser GM, Malpas JS, Oliver RT (1983) Treatment with gonadotropin-releasing hormone analogue in advanced prostatic cancer. Br Med J Clin Res Ed 286:1309–1312

    Article  PubMed  CAS  Google Scholar 

  • Zagars GK, von Eschenbach AC (1993) Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiotherapy. Cancer 72:538–548

    CAS  Google Scholar 

  • Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ (1994a) Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43:828–833

    Article  PubMed  CAS  Google Scholar 

  • Zietman AL, Shipley WU, Coen JJ (1994b) Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate. New insights into outcome from repeat biopsy and prostate specific antigen follow-up. J Urol 152:1806–1812

    CAS  Google Scholar 

Download references

Authors
  1. F. Labrie
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pitié-Salpétrière Hospital SOMPS, 47, bd de l’Hôpital, 75651, Paris Cedex 13, France

    David Khayat

  2. MD Anderson Cancer Center, Department of Breast Medical Oncology, University of Texas, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA

    Gabriel N. Hortobagyi

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag France

About this chapter

Cite this chapter

Labrie, F. (2000). Prostate Cancer and Combined Androgen Blockade at All Stages of Disease. In: Khayat, D., Hortobagyi, G.N. (eds) Progress in Anti-Cancer Chemotherapy. Progress in Anti-Cancer Chemotherapy, vol 4. Springer, Paris. https://doi.org/10.1007/978-2-8178-0920-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0920-5_12

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-59692-6

  • Online ISBN: 978-2-8178-0920-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation